Wockhardt’s UK Business Grows But Other Markets Underperform
Company Sees Major Growth Come From COVID-19 Vaccine Business
Wockhardt has seen a good financial fourth quarter and full year for its UK business, which contributed 41% of the company’s global revenue in Q4 FY21 and 37% to its global revenue for the financial year thanks to its COVID-19 vaccine business. However, the company’s US, India, Ireland and emerging markets businesses delivered a weak fourth quarter.
